explore -WSS

explore

author：hotspot 2025-09-07 04:04:45 - browse：299

AstraZeneca said Friday it will buy up a group of early-stage gene therapies from Pfizer, bucking a trend of drugmakers axing programs and exiting a field that had once captured the imagination — and checkbooks — of many pharmaceutical executives.

AstraZeneca will pay Pfizer up to $1 billion plus royalties for the portfolio of treatments, none of which has entered clinical trials yet. The companies did not say how much it is paying upfront.

The moves come six months after Pfizer said it would stop much of its work on early-stage gene therapy programs, in which researchers try to deliver replacement genes encased in small, non-pathogenic bugs called adeno-associated viruses, or AAVs. Instead, it would focus on newer technologies, such as gene editing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： In utero gene editing: an explainer

entertainment

WSS

Why are Kaiser Permanente staff considering a strike?

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

He's a Nobel laureate. Critics say he was misleading on Covid

CDC advisers recommend seasonal use of Pfizer RSV shot

STAT Virtual Event: Putting AI to the Test

Alabama frozen embryo ruling has major implications for IVF clinics

hotspot

explore

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

How AI helped researchers track recovery from depression

Tori Bowie and the unacceptable rates of Black maternal death

Second xenotransplant done with gene

DIEP, the 'gold standard' of breast reconstruction, is under threat

Emergency workers more likely to restrain Black patients: study

Wildfire smoke exposes gaps in outdoor worker protections

EpiPen alternative approval delay highlights citizen petition issue

Anesthesiologist group: stop taking Ozempic before surgery

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

leisure time

STAT Virtual Event: Putting AI to the Test

STAT readers on older presidents, polypills, Medicare, and more

In utero gene editing: an explainer

New documents shed light on MD Anderson Cancer Institute feud

CDC's new outbreak response network to include Northeastern

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

entertainment

knowledge

hotspot

hotspot